Figure 1
Impact of risk stratification on overall survival. (A) Kaplan-Meier curves comparing the OS from diagnosis among the high- and standard-risk GEP (GEP70) patients receiving initial therapy with lenalidomide and dexamethasone. (B) Kaplan-Meier curves comparing the OS from diagnosis among the high- and standard-risk patients based on GEP (GEP70) and FISH abnormalities, receiving initial therapy with lenalidomide and dexamethasone. (C) Kaplan-Meier curves comparing the OS from diagnosis among the high- and standard-risk patients based on GEP15 score, receiving initial therapy with lenalidomide and dexamethasone.

Impact of risk stratification on overall survival. (A) Kaplan-Meier curves comparing the OS from diagnosis among the high- and standard-risk GEP (GEP70) patients receiving initial therapy with lenalidomide and dexamethasone. (B) Kaplan-Meier curves comparing the OS from diagnosis among the high- and standard-risk patients based on GEP (GEP70) and FISH abnormalities, receiving initial therapy with lenalidomide and dexamethasone. (C) Kaplan-Meier curves comparing the OS from diagnosis among the high- and standard-risk patients based on GEP15 score, receiving initial therapy with lenalidomide and dexamethasone.

Close Modal

or Create an Account

Close Modal
Close Modal